Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care

• Published in: The American heart journal Vol. 247; pp. 132 - 148
• Main Authors: Persson Lindell, Olof, Karlsson, Lars O, Nilsson, Staffan, Charitakis, Emmanouil, Hagström, Emil, Muhr, Thomas, Nilsson, Lennart, Henriksson, Martin, Janzon, Magnus
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2022; Elsevier Limited
• Subjects: Arteriosclerosis; Atherosclerosis; Cardiology; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Cholesterol, LDL; Clinics; Clusters; Collaboration; Coronary artery; Coronary artery disease; Coronary vessels; Cost analysis; Decision support systems; Decision Support Systems, Clinical; Electronic health records; Electronic medical records; Evaluation; Genetic disorders; Health care; Health risks; Heart diseases; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II - drug therapy; Hyperlipoproteinemia Type II - therapy; Intervention; Laboratories; Lipids; Medical referrals; Patients; Physicians; Primary care; Primary Health Care; Stroke; Triglycerides; Vein & artery diseases; Sweden
• ISSN: 0002-8703; 1097-6744; 1097-6744
• DOI: 10.1016/j.ahj.2022.02.005

: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder with high risk of premature atherosclerotic cardiovascular disease and death. Clinical decision support (CDS) systems have the potential to aid in the identification and management of patients with FH. Prior studies using computer-based systems to screen patients for FH have shown promising results, but there has been no randomized controlled trial conducted. The aim of the current cluster randomized study is to evaluate if a CDS can increase the identification of FH. : We have developed a CDS integrated in the electronic health records that will be activated in patients with elevated cholesterol levels (total cholesterol >8 mmol/L or low-density lipoprotein-cholesterol >5.5 mmol/L, adjusted for age, ongoing lipid lowering therapy and presence of premature coronary artery disease) at increased risk for FH. When activated, the CDS will urge the physician to send an automatically generated referral to the local lipid clinic for further evaluation. To evaluate the effects of the CDS, all primary care clinics will be cluster randomized 1:1 to either CDS intervention or standard care in a Swedish region with almost 500,000 inhabitants. The primary endpoint will be the number of patients diagnosed with FH at 30 months. Resource use and long-term health consequences will be estimated to assess the cost-effectiveness of the intervention. : Despite increasing awareness of FH, the condition remains underdiagnosed and undertreated. The present study will investigate whether a CDS can increase the number of patients being diagnosed with FH.